Cargando…

Tumor-Associated Antigen xCT and Mutant-p53 as Molecular Targets for New Combinatorial Antitumor Strategies

The cystine/glutamate antiporter xCT is a tumor-associated antigen that has been newly identified in many cancer types. By participating in glutathione biosynthesis, xCT protects cancer cells from oxidative stress conditions and ferroptosis, and contributes to metabolic reprogramming, thus promoting...

Descripción completa

Detalles Bibliográficos
Autores principales:	Magri, Jolanda, Gasparetto, Alessandro, Conti, Laura, Calautti, Enzo, Cossu, Chiara, Ruiu, Roberto, Barutello, Giuseppina, Cavallo, Federica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827209/ https://www.ncbi.nlm.nih.gov/pubmed/33430127 http://dx.doi.org/10.3390/cells10010108

Ejemplares similares

Cystine/glutamate antiporter xCT deficiency reduces metastasis without impairing immune system function in breast cancer mouse models
por: Ruiu, Roberto, et al.
Publicado: (2023)

Immunotherapy against the Cystine/Glutamate Antiporter xCT Improves the Efficacy of APR-246 in Preclinical Breast Cancer Models
por: Barutello, Giuseppina, et al.
Publicado: (2022)

Development of a VLP-Based Vaccine Displaying an xCT Extracellular Domain for the Treatment of Metastatic Breast Cancer
por: Rolih, Valeria, et al.
Publicado: (2020)

Microenvironment, Oncoantigens, and Antitumor Vaccination: Lessons Learned from BALB-neuT Mice
por: Conti, Laura, et al.
Publicado: (2014)

A Virus-Like-Particle immunotherapy targeting Epitope-Specific anti-xCT expressed on cancer stem cell inhibits the progression of metastatic cancer in vivo
por: Bolli, Elisabetta, et al.
Publicado: (2017)

Cystine–glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity
por: Arensman, Michael D., et al.
Publicado: (2019)

Identification of TENM4 as a Novel Cancer Stem Cell-Associated Molecule and Potential Target in Triple Negative Breast Cancer
por: Ruiu, Roberto, et al.
Publicado: (2021)

STEAP3 Affects Ferroptosis and Progression of Renal Cell Carcinoma Through the p53/xCT Pathway
por: Ye, Cheng Lin, et al.
Publicado: (2022)

Teneurins: Role in Cancer and Potential Role as Diagnostic Biomarkers and Targets for Therapy
por: Peppino, Giulia, et al.
Publicado: (2021)

xCT increases tuberculosis susceptibility by regulating antimicrobial function and inflammation
por: Cai, Yi, et al.
Publicado: (2016)

Participation of xCT in melanoma cell proliferation in vitro and tumorigenesis in vivo
por: Shin, Seung-Shick, et al.
Publicado: (2018)

Functional analysis of CD44 variants and xCT in canine tumours
por: Tanabe, Atsushi, et al.
Publicado: (2020)

Decreased xCT activity in patients associated with Helicobacter pylori infection
por: Wang, Ling, et al.
Publicado: (2022)

Antitumor immunization of mothers delays tumor development in cancer-prone offspring
por: Barutello, Giuseppina, et al.
Publicado: (2015)

Genomic analysis of xCT-regulatory network in KSHV + primary effusion lymphomas
por: Qin, Zhiqiang, et al.
Publicado: (2016)

xCT inhibition sensitizes tumors to γ-radiation via glutathione reduction
por: Cobler, Lara, et al.
Publicado: (2018)

xCT Inhibition Increases Sensitivity to Vorinostat in a ROS-Dependent Manner
por: Miyamoto, Keiko, et al.
Publicado: (2020)

Sulfasalazine Sensitizes Polyhematoporphyrin-Mediated Photodynamic Therapy in Cholangiocarcinoma by Targeting xCT
por: Zheng, Yan-Wen, et al.
Publicado: (2021)

Structure‐Activity‐Relationship‐Aided Design and Synthesis of xCT Antiporter Inhibitors
por: Cirillo, Davide, et al.
Publicado: (2021)

Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs’ Revolution for Immunotherapy
por: Barutello, Giuseppina, et al.
Publicado: (2018)

The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility
por: Shin, Chun-Shik, et al.
Publicado: (2017)

Maternal Immunization: New Perspectives on Its Application Against Non-Infectious Related Diseases in Newborns
por: Riccardo, Federica, et al.
Publicado: (2017)

Overexpression of xCT induces up-regulation of 14-3-3β in Kaposi's sarcoma
por: Zeng, Yan, et al.
Publicado: (2010)

Histone deacetylases inhibition by SAHA/Vorinostat normalizes the glioma microenvironment via xCT equilibration
por: Wolf, Ines M. L., et al.
Publicado: (2014)

Implication of the glutamate–cystine antiporter xCT in schizophrenia cases linked to impaired GSH synthesis
por: Fournier, M., et al.
Publicado: (2017)

Cystine/Glutamate Antiporter (xCT) Is Required for Chief Cell Plasticity After Gastric Injury
por: Meyer, Anne R., et al.
Publicado: (2019)

Chemotherapeutic xCT inhibitors sorafenib and erastin unraveled with the synaptic optogenetic function analysis tool
por: Dahlmanns, Marc, et al.
Publicado: (2017)

CD44 and xCT: The Silver Bullet for Endothelial-to-Mesenchymal Transition in Pulmonary Arterial Hypertension?
por: Agrawal, Vineet, et al.
Publicado: (2019)

The Role of Cystine/Glutamate Antiporter SLC7A11/xCT in the Pathophysiology of Cancer
por: Jyotsana, Nidhi, et al.
Publicado: (2022)

A xCT role in tumour-associated ferroptosis shed light on novel therapeutic options
por: Criscuolo, Daniela, et al.
Publicado: (2022)

CIC reduces xCT/SLC7A11 expression and glutamate release in glioma
por: Park, Jong-Whi, et al.
Publicado: (2023)

Akt modes of stem cell regulation: more than meets the eye?
por: Calautti, Enzo
Publicado: (2013)

Role and Involvement of TENM4 and miR-708 in Breast Cancer Development and Therapy
por: Peppino, Giulia, et al.
Publicado: (2022)

Are Cancer Stem Cells a Suitable Target for Breast Cancer Immunotherapy?
por: Ruiu, Roberto, et al.
Publicado: (2022)

AKT activation because of PTEN loss upregulates xCT via GSK3β/NRF2, leading to inhibition of ferroptosis in PTEN-mutant tumor cells
por: Cahuzac, Kaitlyn M., et al.
Publicado: (2023)

Impaired long-term potentiation and long-term memory deficits in xCT-deficient sut mice
por: Li, Yan, et al.
Publicado: (2012)

xCT knockdown in human breast cancer cells delays onset of cancer-induced bone pain
por: Ungard, Robert G, et al.
Publicado: (2019)

Vasodilator oxyfedrine inhibits aldehyde metabolism and thereby sensitizes cancer cells to xCT‐targeted therapy
por: Otsuki, Yuji, et al.
Publicado: (2019)

xCT-Driven Expression of GPX4 Determines Sensitivity of Breast Cancer Cells to Ferroptosis Inducers
por: Lee, Namgyu, et al.
Publicado: (2021)

The Styryl Benzoic Acid Derivative DC10 Potentiates Radiotherapy by Targeting the xCT-Glutathione Axis
por: Sarowar, Shahin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_16ta5vko128s8q15ka1iidr27n